Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · lung-landscapes@6

TCGA-52-7811-01A-11R-2125-07

— · cohortSQ1

f6b21d86-af46-5752-b2e4-ca0501358f14

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
cohortSQ1
subtype
cohortSQ1
age_years
67

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • TNFA_SIGNALING_VIA_NFKB+0.440
  • ANGIOGENESIS+0.430
  • MYC_TARGETS_V1+0.430
  • MYC_TARGETS_V2+0.410
  • CHOLESTEROL_HOMEOSTASIS+0.380
  • MTORC1_SIGNALING+0.380
  • OXIDATIVE_PHOSPHORYLATION+0.380
  • APICAL_SURFACE+0.370
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.370
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.350

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.280
  • BILE_ACID_METABOLISM-0.060
  • HEDGEHOG_SIGNALING-0.060
  • INTERFERON_GAMMA_RESPONSE-0.060
  • DNA_REPAIR-0.030
  • NOTCH_SIGNALING+0.010
  • PEROXISOME+0.010
  • ALLOGRAFT_REJECTION+0.020
  • PROTEIN_SECRETION+0.020
  • KRAS_SIGNALING_DN+0.040

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR11296801
colon-landscapes@1
——0.891
2TCGA-51-4079-01A-01R-1100-07
lung-landscapes@6
—cohortSQ20.877
3TCGA-18-3417-01A-01R-1443-07
lung-landscapes@6
—cohortSQ10.857
4TCGA-68-7756-01A-11R-2125-07
lung-landscapes@6
—cohortSQ10.850
5TCGA-66-2734-01A-01R-0980-07
lung-landscapes@6
—cohortSQ10.849
620060039.TNBC
breast-umap@18
—C0.848
7MNG688
mng-umap@100
——0.848
8R275
bladder-landscape@3
——0.846
9TCGA-77-7337-01A-21R-2045-07
lung-landscapes@6
—cohortSQ10.844
10MDT-AP-0370
medullo-epn-umap@date-based
MedMedulloblastoma0.844

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 45 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
TNFA_SIGNALING_VIA_NFKB0.440Inavolisib— uncovered
ANGIOGENESIS0.430Remibrutinib— uncovered
MYC_TARGETS_V10.430Inavolisib— uncovered
MYC_TARGETS_V20.410Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.380Remibrutinib— uncovered
MTORC1_SIGNALING0.380Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.380Remibrutinib— uncovered
APICAL_SURFACE0.370Temsirolimus— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.370Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.350Inavolisib— uncovered
APICAL_JUNCTION0.320Inavolisib— uncovered
COAGULATION0.310Binimetinib— uncovered
HYPOXIA0.310Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.310Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.300Idelalisib— uncovered
ADIPOGENESIS0.290Inavolisib— uncovered
ANDROGEN_RESPONSE0.290Inavolisib— uncovered
G2M_CHECKPOINT0.280Inavolisib— uncovered
COMPLEMENT0.260Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.260Idelalisib— uncovered